INDSWFTLAB

Ind-Swift Laboratories Share PriceInd-Swift Laboratories

₹65.5
0.6 (0.92%)
As on 07 February, 2023 | 03:49 BSE: 532305 NSE: INDSWFTLAB

Ind-Swift Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Ind-Swift Laboratories

Start SIP

Ind-Swift Laboratories Share Price

  • Over 1 Month -1.43%
  • Over 3 Month 21.86%
  • Over 6 Month 7.29%
  • Over 1 Year -22.49%

Ind-Swift Laboratories Key Statistics

P/E Ratio -1921.9
PEG Ratio 19.1
Market Cap Cr 387
Price to Book Ratio 1
EPS -0.4
Dividend 0
Relative Strength Index 47.4
Money Flow Index 56.68
MACD Signal -0.12
Average True Range 2.48

Ind-Swift Laboratories Investment Rating

  • Master Rating:
  • Ind-Swift Labs. (Nse) has an operating revenue of Rs. 1,143.67 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 1% needs improvement, ROE of -0% is poor and needs improvement. The company has a high debt to equity of 210%, which can be a reason to worry. The stock from a technical standpoint is trading below to its 50DMA and around 5% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 41 which is a POOR score indicating inconsistency in earnings, a RS Rating of 60 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Ind-Swift Laboratories Financials
IndicatorSep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 288272276
Operating Expenses Qtr Cr 231219241
Operating Profit Qtr Cr 575335
Depreciation Qtr Cr 161682
Interest Qtr Cr 242423
Tax Qtr Cr 0014
Net Profit Qtr Cr 2420-63

Ind-Swift Laboratories Technicals

EMA & SMA

Current Price
₹65.5
0.6 (0.92%)
  • Bullish Moving Average
  • ___
  • 11
  • Bearish Moving Average
  • ___
  • 5
  • 20 Day
  • 65.74
  • 50 Day
  • 65.19
  • 100 Day
  • 63.8
  • 200 Day
  • 63.79
  • 20 Day
  • 65.95
  • 50 Day
  • 66.19
  • 100 Day
  • 62.1
  • 200 Day
  • 61.33

Ind-Swift Laboratories Resistance and Support

PIVOT
₹64.87
Resistance
First Resistance 65.94
Second Resistance 66.97
Third Resistance 68.04
RSI 47.4
MFI 56.68
MACD Single Line -0.12
MACD -0.31
Support
First Resistance 63.84
Second Resistance 62.77
Third Resistance 61.74

Ind-Swift Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 54,483 4,050,811 74.35
Week 50,972 3,629,688 71.21
1 Month 49,653 3,414,644 68.77
6 Month 79,652 4,664,435 58.56

Ind-Swift Laboratories Result Highlights

Ind-Swift Laboratories Synopsis

NSE-Medical-Generic Drugs

Ind-Swift Laboratori is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 988.09 Cr. and Equity Capital is Rs. 59.81 Cr. for the Year ended 31/03/2022. Ind-Swift Laboratories Ltd. is a Public Limited Listed company incorporated on 04/01/1995 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1995PLC015553 and registration number is 015553.
Market Cap 385
Sales 1,075
Shares in Float 3.43
No of funds 5
Yield
Book Value 0.89
U/D Vol ratio 1.9
LTDebt / Equity 192
Alpha -0.09
Beta 0.81

Ind-Swift Laboratories

Owner NameDec-22Sep-22Jun-22Mar-22
Promoters 42%42%42%
Foreign Portfolio Investors 0.04%
Individual Investors 28.97%29.06%29.55%
Others 28.99%28.94%28.45%

Ind-Swift Laboratories Management

Name Designation
Mr. N R Munjal Chairman & Managing Director
Mr. Himanshu Jain Joint Managing Director
Mr. Rishav Mehta Executive Director
Mr. Sahil Munjal Executive Director
Dr. Ashwani Kumar Vig Independent Director
Mr. Rajinder Kumar Gupta Independent Director
Mr. S P Sharma Independent Director
Ms. Neerja Chathley Independent Woman Director

Ind-Swift Laboratories Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Ind-Swift Laboratories Corporate Action

Date Purpose Remarks
2023-02-14 Quarterly Results
2022-11-08 Quarterly Results
2022-08-10 Quarterly Results
2022-05-28 Audited Results
2022-02-08 Quarterly Results

Ind-Swift Laboratories MF Shareholding

Name Amount(cr)
Motilal Oswal S&P BSE Healthcare ETF 6

Ind-Swift Laboratories FAQs

What is Share Price of Ind-Swift Laboratories ?

Ind-Swift Laboratories share price is ₹65 As on 07 February, 2023 | 03:35

What is the Market Cap of Ind-Swift Laboratories ?

The Market Cap of Ind-Swift Laboratories is ₹387 Cr As on 07 February, 2023 | 03:35

What is the P/E ratio of Ind-Swift Laboratories ?

The P/E ratio of Ind-Swift Laboratories is -1921.9 As on 07 February, 2023 | 03:35

What is the PB ratio of Ind-Swift Laboratories ?

The PB ratio of Ind-Swift Laboratories is 1 As on 07 February, 2023 | 03:35

Q2FY23